Immunotherapeutic implications of IL-6 blockade for cytokine storm.

638 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cytokine release syndrome (2018, positive): “Via trans-signaling IL-6 leads to characteristic symptoms of severe CRS, i.e. vascular leakage, and activation of the complement and coagulation cascade inducing disseminated intravascular coagulation (DIC) [57, 60].”
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? (2020, positive): “Excessive IL-6 signaling leads to a myriad of biological effects that contribute to organ damage, such as maturing naïve T cells into effector T cells, inducing vascular endothelial growth factor (VEGF) expression in epithelial cells, increasing vessel permeability [30], and reducing myocardium cont”
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease (2020, positive): “For this reason, some therapeutic strategies have used the inhibition of IL-1 in an attempt to avoid the cytokine storm [59,60].”
Diabetes is a risk factor for the progression and prognosis of COVID‐19 (2020, neutral): “5-81] vs 23 [10-49]), as well as D-dimer (1.”